Swedish Orphan Biovitrum
kr 427.80Change from previous close: −1.52%Absolute change: −kr 6.60
At a glance
- Revenue growth
- +8.50%
- 2025 vs 2024
- Net income growth
- −87.70%
- 2025 vs 2024
- Net margin
- 1.7%
- 2024: 14.9%
Financial data
Amounts in millions of SEK; per-share values in SEK; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 8,565 | 7,388 | 4,470 | 4,576 | 5,470 |
| Depreciation and amortization | 3,415 | 3,589 | 3,030 | 2,190 | 1,924 |
| Capital expenditure | -40.0 | -170 | -873 | -72.0 | -47.0 |
| Investing cash flow | -4,294 | -3,091 | -21,904 | -1,477 | -367 |
| Financing cash flow | -4,323 | -4,001 | 17,012 | -2,902 | -4,474 |
| Debt issued | 3,055 | 14,220 | 35,876 | 13,675 | — |
| Debt repaid | -7,987 | -18,656 | -24,628 | -16,094 | — |
| Effect of exchange rates | -46.0 | -61.0 | -35.0 | 119 | 12.0 |
| Net change in cash | -99.0 | 236 | -457 | 316 | 641 |
| Free cash flow | 8,525 | 7,218 | 3,597 | 4,504 | 5,423 |
| Levered free cash flow | 5,223 | 1,529 | 504 | 3,535 | 4,485 |